Preventing certain bone-related events in patients who have a certain type of tumor that has spread to the bones (bone metastases). It may also be used to treat certain patients with giant-cell tumor of bone that cannot be removed by surgery. Xgeva is a receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor. It works by slowing bone loss and increasing bone strength. This helps to reduce the risk of bone-related events in patients with cancer that has spread to the bone.
Xgeva is used to treat osteoporosis in both men and women, as well preventing bone fractures in people who have had cancer spread to their bones. Xgeva uses antibodies to seek and destroy particular cells within the body, thus saving healthy cells.